The University of Southampton
×
Filter your search:
University of Southampton Institutional Repository

Management of relapsed or refractory large B-cell lymphoma: a British Society for Haematology Guideline

Management of relapsed or refractory large B-cell lymphoma: a British Society for Haematology Guideline
Management of relapsed or refractory large B-cell lymphoma: a British Society for Haematology Guideline

Time to progression is the strongest predictor of outcome in relapsed diffuse large B-cell lymphoma. Second-line treatment with chimeric antigen receptor (CAR) T-cell therapy is recommended for patients with progression within 12 months of first-line chemoimmunotherapy. In patients with late relapse, platinum-based chemotherapy followed by high-dose chemotherapy with autologous stem cell rescue is recommended. In second relapse, CAR T-cell or CD3xCD20 bispecific antibody therapy is recommended in eligible patients. Other treatment options are available for less fit patients. Specific recommendations are made on diagnostic immunohistochemistry, bendamustine use and bridging to CAR T-cell therapy.

antibody therapy, B-cell lymphoma, cellular therapies, immunotherapies, non-Hodgkin lymphoma
0007-1048
1593-1603
Chaganti, Sridhar
d4833441-7780-4dd3-96ca-24bda56ca894
Fox, Christopher P.
9ddc7032-e310-491d-a1b9-85d724d0bb50
Maybury, Bernard D.
09a29a45-4da9-4ef8-8ce5-753001d8b32b
Burton, Cathy
e173dfe8-9139-422e-8ab0-f97a9c24fa9a
Barrington, Sally F.
fb047bda-27e7-4082-b741-c41ef52aa53c
Illidge, Timothy
9abbc831-d66d-4288-8dc4-d2e1ad45d782
Kalakonda, Nagesh
c3b15004-be3f-4fd8-afee-9f1c3a664a0b
Eyre, Toby A.
f4095fe6-217a-492c-ba99-ad5efaa4c879
McKay, Pam
aa139813-ec16-4255-ba75-043f685a52d2
Kuhnl, Andrea
20e89ec1-8618-48c5-97c2-e3e9a709fb46
Cwynarski, Kate
34d6aef4-8106-40ee-9609-b44460ccb971
Davies, Andrew J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
the BSH Committee
Chaganti, Sridhar
d4833441-7780-4dd3-96ca-24bda56ca894
Fox, Christopher P.
9ddc7032-e310-491d-a1b9-85d724d0bb50
Maybury, Bernard D.
09a29a45-4da9-4ef8-8ce5-753001d8b32b
Burton, Cathy
e173dfe8-9139-422e-8ab0-f97a9c24fa9a
Barrington, Sally F.
fb047bda-27e7-4082-b741-c41ef52aa53c
Illidge, Timothy
9abbc831-d66d-4288-8dc4-d2e1ad45d782
Kalakonda, Nagesh
c3b15004-be3f-4fd8-afee-9f1c3a664a0b
Eyre, Toby A.
f4095fe6-217a-492c-ba99-ad5efaa4c879
McKay, Pam
aa139813-ec16-4255-ba75-043f685a52d2
Kuhnl, Andrea
20e89ec1-8618-48c5-97c2-e3e9a709fb46
Cwynarski, Kate
34d6aef4-8106-40ee-9609-b44460ccb971
Davies, Andrew J.
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af

the BSH Committee (2025) Management of relapsed or refractory large B-cell lymphoma: a British Society for Haematology Guideline. British Journal of Haematology, 206 (6), 1593-1603. (doi:10.1111/bjh.20129).

Record type: Article

Abstract

Time to progression is the strongest predictor of outcome in relapsed diffuse large B-cell lymphoma. Second-line treatment with chimeric antigen receptor (CAR) T-cell therapy is recommended for patients with progression within 12 months of first-line chemoimmunotherapy. In patients with late relapse, platinum-based chemotherapy followed by high-dose chemotherapy with autologous stem cell rescue is recommended. In second relapse, CAR T-cell or CD3xCD20 bispecific antibody therapy is recommended in eligible patients. Other treatment options are available for less fit patients. Specific recommendations are made on diagnostic immunohistochemistry, bendamustine use and bridging to CAR T-cell therapy.

Text
Relapsed-refractory_large_B_cell_lymphoma_GL_SECOND_REVISION_003_ (1) - Accepted Manuscript
Restricted to Repository staff only until 19 May 2026.
Available under License University of Southampton Accepted Manuscript Licence.
Request a copy
Text
Relapsed-refractory large B cell lymphoma GL SECOND REVISION (003)
Restricted to Repository staff only
Available under License University of Southampton Accepted Manuscript Licence.
Request a copy

More information

Accepted/In Press date: 18 April 2025
e-pub ahead of print date: 19 May 2025
Published date: 13 June 2025
Keywords: antibody therapy, B-cell lymphoma, cellular therapies, immunotherapies, non-Hodgkin lymphoma

Identifiers

Local EPrints ID: 504038
URI: http://eprints.soton.ac.uk/id/eprint/504038
DOI: doi:10.1111/bjh.20129
ISSN: 0007-1048
PURE UUID: 5bb4309f-2276-4150-abd9-84fd552d22d9
ORCID for Andrew J. Davies: ORCID iD orcid.org/0000-0002-7517-6938

Catalogue record

Date deposited: 21 Aug 2025 16:07
Last modified: 22 Aug 2025 01:59

Export record

Altmetrics

Contributors

Author: Sridhar Chaganti
Author: Christopher P. Fox
Author: Bernard D. Maybury
Author: Cathy Burton
Author: Sally F. Barrington
Author: Timothy Illidge
Author: Nagesh Kalakonda
Author: Toby A. Eyre
Author: Pam McKay
Author: Andrea Kuhnl
Author: Kate Cwynarski
Author: Andrew J. Davies ORCID iD
Corporate Author: the BSH Committee

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Library staff additional information
Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×